market strategy using patent data analysis mark d. bauer online services derwent north america
TRANSCRIPT
Market Strategy Using Patent Data Analysis
Mark D. Bauer
Online Services
Derwent North America
Discussion Topics
• Introduction
• Strategy
• Questions
• Drilling Techniques
• Assumptions
• Conclusions
• Unique resource
• Geography
• Chronology
• The Marketplace
• The Sharp Advantage
• Commercial Databases
• Case study
Introduction
Unique Resource
• Hard Data
• Technology & Market Profile
• Prosecution and Maintenance– $250,000 = 1 patent
Strategy
• Portfolio Management
• Licensing Technology
• Patent Value vs. Investment
• Corporate Goals
Questions
• Where are the Competitors?– Priority Country
• Where is the Market?– Publication Country
• Who are the New players?– Patentee Codes
• Do Industry Icons Develop the New Technology?– Patent Classification
Drilling Techniques
PFIZ - Patentee CodeDerwent Codes for
CNS and Tranquilizers
450 hits
SSRI,Serotonin & Inhibit?
& Pfizer16 hits
Drilling Techniques
KeywordsCompany
NamesDates
ClassificationsCodesIndexing
SSRI,Serotonin& PFIZ
& CODES38 hits
ModifiedKeywordsCompany
NamesDatesCodes
Drilling Techniques
• Pharmaceuticals in 2000
– US 13070– EPO equiv. 922– WO equiv. 9074
Assumptions
• Data must be viewed as subject to various factors– Full Text– Backfile– Subject Coverage– Country Coverage– Quality
Assumptions
• Patent Issuing Authority– Australian PCT Pubs– Japanese Kokai– Germany & Spain EP pubs– National Phase PCT
• Prosecution Strategy– minimize exposure– maximize exposure
0
20
40
60
80
100
120
140
160
Number of Inventions
1980 1981 1982 1983 1984 1986 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001Basic Publication Year
IBM patents filed as PCT
IBM Patents filed as PCT - Comparison of PCTs vs Total
0
500
1000
1500
2000
2500
3000
3500
4000
1980 1981 1982 1983 1984 1986 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
Basic Publication Year
PCT
Total
SSRI Patent Activity by Priority Year
0
20
40
60
80
100
120
140
160
1957
1961
1963
1965
1967
1969
1971
1974
1976
1978
1980
1982
1984
1986
1988
1990
1992
1994
1996
1998
2000
Priority Year
Nu
mb
er
of
Inv
en
tio
ns
0
20
40
60
80
100
120
140
160
Number of Inventions
1957
1961
1963
1965
1967
1969
1971
1974
1976
1978
1980
1982
1984
1986
1988
1990
1992
1994
1996
1998
2000
Priority Year
SSRI Granted vs Total of Applications
Granted Patents Total of All Applications
SSRI Patent Activity by Priority Country
0
50
100
150
200
250
300
350
400
450
500
US
GB JP FR
DE
CH
EP
DK IT
WO ES
SE
AU ZA IN SU
BR
CA
HU
BE
CN IE NL
HR
AR
CS
KR
MX
NO PH
RO
TW YU
WIPO Country Codes
Nu
mb
er
of
Inv
en
tio
ns
1957
1961
1963
1965
1967
1969
1971
1974
1976
1978
1980
1982
1984
1986
1988
1990
1992
1994
1996
1998
2000
AR
CS
NL
YU
DK
FR
0
10
20
30
40
50
60
70
80
90
Number of Inventions
Priority Year
WIPO Country Codes
SSRI Patent Activity - Priority Year/Country
1957
1961
1963
1965
1967
1969
1971
1974
1976
1978
1980
1982
1984
1986
1988
1990
1992
1994
1996
1998
2000
WO
IT
GB
0
10
20
30
40
50
60
70
80
90
SSRI in Major Countries
WO
DK
DE
EP
IT
SE
JP
FR
GB
US
1957
1961
1963
1965
1967
1969
1971
1974
1976
1978
1980
1982
1984
1986
1988
1990
1992
1994
1996
1998
2000
TW
BR
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
SSRI in Minor Countries
TW
YU
ZA
BR
ES
IN
1957
1961
1963
1965
1967
1969
1971
1974
1976
1978
1980
1982
1984
1986
1988
1990
1992
1994
1996
1998
2000
AR
CH
0
0.5
1
1.5
2
2.5
3
3.5
4
SSRI Minor Countries
AR
AU
BE
CA
CH
CN
CS
HR
Highly Cited Patents
TI New 1-(hetero)aryl-3-piperazino or tetra hydro pyridyl-1H-indole cpds. - are dopaminergic and 5-HT antagonists useful for treating psychoses.
DC B02
IN PERREGAARD, J K
PA (LUND) LUNDBECK H A/S; (LUND) LUNDBECK AS H
CYC 23
PI EP 200322 A 19861105 (198645)* EN 33p
PNC.GX 96 Citing Patents Count (by examiner)
Highly Cited Patents
TI Benzoic acid piperidyl ester(s) contg. alkylene bridges - in piperidyl ring are used as antipsychotics for treatment of cardiac-circulatory disorders.
DC B02 B03
IN ENGEL, G; HUEGI, B; RICHARDSON, B P; STADLER, P; DONATSCH, P; HUGI, B; STADLER, P A
PA (DONA-I) DONATSCH P; (SANO) SANDOZ AG; (SANO) SANDOZ PATENT GMBH; (NOVS) NOVARTIS AG; (SANO) SANDOZ LTD
CYC 21
PI DE 3322574 A 19831229 (198402)* 62p
PNC.GX 179 Citing Patents Count (by examiner)
Conclusions
• New Pieces for Puzzle
• Global View of Market
• Comprehensive Technology Review
